The nation’s pharmaceutical exports increased 9.4% in 2024–2025 to USD 30.47 billion, according to the commerce ministry on Saturday. The industry is hoping for a double-digit growth in 2026–2027.
During Chintan Shivir in Ahmedabad, Government officials and industry representatives discussed issues related to pharmaceutical exports. By 2030, the industry, which is currently worth about USD 60 billion, is expected to grow to USD 130 billion.
India exports medications to more than 200 markets, with over 60% of those exports going to markets with strict regulations, placing it third in the world by volume. “The discussion emphasized the government’s focus on enabling conditions for sustained export acceleration, with industry indicating preparedness to pursue double-digit growth in 2026-27,” the statement stated. Of India’s pharmaceutical exports, 34% go to the US and 19% go to Europe.
“Talk about engagement with the European Union was surrounding a pharmaceutical deal for USD 572.3 billion and market for medical devices, and a bilateral trade agreement with the US can enhance market accessibility even more and cost-effectiveness for Indian pharmaceutical firms,” the statement continued, adding that exporters were also informed of opportunities resulting from recent trade engagements with important partners, including the United States and the European Union.
In order to guarantee prompt problem identification and resolution and assist long-term growth in pharmaceutical exports in international markets, the ministry also stated that it will keep interacting with exporters, regulators, and Indian missions overseas.
